Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

ATR kinase blockade useful for treating pancreatic ductal adenocarcinoma

Jan. 19, 2022

Avacta selects FAP-targeted proteasome inhibitor for preclinical development

Jan. 18, 2022

MCC-1381, a pan-HDAC inhibitor with promising anticancer activity

Jan. 18, 2022

EZH2 as a promising therapeutic target for prostate cancer

Jan. 18, 2022

Purdue Research Foundation patents protein kinase inhibitors

Jan. 18, 2022

Preclinical data confirm anticancer activity of two lead compounds in Captor's CT-01 program in HCC

Jan. 17, 2022

AstraZeneca and Scorpion collaborate on therapeutics against transcription factors for cancer

Jan. 17, 2022

New 3,5-diaryl-substituted pyrazoles inhibit prostate cancer cell growth

Jan. 17, 2022

Celgene presents new cereblon-binding PROTACs

Jan. 17, 2022

Novel ER modulator daidzein analogues confer antitumoral effect in prostate cancer

Jan. 17, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...